Abstract:Objective To observe the therapeutic effect and adverse reactions of recombinant mutant human tumor necrosis factor(rmh-TNF)combined cisplatin in the treatment of lung cancer with malignant pleural effusion. Methods Sixty patients of lung cancer with malignant pleural effusion from January 2013 to December 2014 in our hospital were chosen and randomly divided into treatment group and control group.Treatment group were injected intrapleurally with rmh-TNF combined cisplatin at a dose of 2×106U and 30 mg after complete drainage,once a week;control group were injected intrapleurally with cisplatin at a dose of 30 mg,once a week,the effect and adverse reactions were observed. Results Among the treatment group,14 patients were complete response(CR),12 patients were partial response(PR)and 4 patients were no change(NC),the overall response rate was 86.7%,among the control group,8 patients were CR,8 patients were PR and 14 patients were NC,the overall response rate was 53.3%,the difference was statistically significant (P<0.01).Common adverse reactions were common chest pain,the incidence of gastrointestinal reaction(malignant,vomiting)in treatment group was 43.3%(13/30),23.3%(7/30)respectively, and was 33.3%(10/30),30.0%(9/30)in control group,the difference was no statistically significant(P>0.05).The incidence of fever in treatment group was 46.7%(14/ 30),and was 16.7% (5/30)in control group,the difference was statistically significant(P<0.05). Conclusion The rmh-TNF combined cisplatin is effective in the treatment of lung cancer with malignant pleural effusion,and with slide adverse reactions.
胡涛;陈晓林;黄玉民;陶玉坚. 重组改构人肿瘤坏死因子联合顺铂治疗肺癌恶性胸腔积液的效果[J]. 中国当代医药, 2016, 23(2): 47-49.
HU Tao;CHEN Xiao-lin;HUANG Yu-min;TAO Yu-jian. The therapeutic effect of rmh-TNF combined cisplatin in treating lung cancer with malignant pleural effusion. 中国当代医药, 2016, 23(2): 47-49.
Wu SG,Yu CJ,Tsai MF,et al.Survival of lung adenocarcinoma patients with malignant pleural effusion[J].Eur Respir J,2013,41(6):1409-1428.
[3]
Postmus PE,Brambilla E,Chansky K,et al.The IASLC Lung Cancer Staging Project:proposals for revision of the M descriptors in the forth-coming(seventh)edition of the TNM classification of lung cancer[J].Thorac Oncol,2007,2 (8):686-693.